Welcome to CrystecPharma
CrystecPharma applies the latest supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.
Applications of our technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics.
Our solutions include the following:
- Crystal and particle engineering
- Stabilisation of therapeutic agents derived from biotechnology
- Polymorph screening
- Improved performance of poorly soluble drugs
- Inhaled therapy
- Taste masking
- Crystallisation seeds
- Residual solvent elimination
Crystec’s Chief Scientist, Professor Peter York recently presented at the 5th Medicon Valley Inhalation Symposium (MVIS)
Professor Peter York, Crystec’s Chief Scientist, recently presented at the 2-day Medicon Valley Inhalation Symposium. His presentation on Day 1, focused on the 'Supercritical Fluid (SCF) Particle Engineering for Optimised Inhaled Delivery'.
October 25 2016
APS International PharmSci conference attended by Crystec’s CEO, Paul Thorning, and Chief Scientist, Professor Peter York
Crystec’s CEO, Paul Thorning, and Chief Scientist, Professor Peter York, were invited to present at the 7th APS International PharmSci conference last week. The event was hosted by the University of Strathclyde and focused on ‘Pharmaceutical Sciences: Improving World Health’.
September 12 2016